A high increase in EMAP+CD3+% was observed in newly diagnosed NHL patients compared to healthy volunteers [median: 24.3% (range: 24-26) and 1.3% (range: 1.3-1.4); P < 0.001, respectively]. This evidence concerns the gene EML1 and non-Hodgkin lymphoma.